MERS-CoV: In one month Greffex builds an advanced vaccine against the Middle East Respiratory Syndrome coronavirus
AURORA, Colo.--(BUSINESS WIRE)--June 26, 2013--A scant two months after creating the first comprehensive vaccine for H7N9 avian influenza, Greffex developed a vaccine to protect against the Middle East Respiratory Syndrome coronavirus (MERS-CoV.) The vaccine was readied in just four weeks after MERS-CoV had moved to the WHO's "alert phase" that also includes the human bird flu viruses H5N1 and H7N9. "We have big competitors who claim they can initiate vaccine production faster than we can," says Dr. Uwe D. Staerz, Chief Scientific Officer at Greffex. "That they can go from algorithm to gene synthesis in matter of days invoking synthetic biology. But after they've constructed the necessary genes, they still need several months to deliver an actual vaccine. Once we get the genetic information for a new virus, we can give you a testable vaccine in a month. Our platform is therefore ideally suited to combat fast emerging infections."